ApoCell and Reata Initiate Phase II Diabetic Renal Disease Trial
Posted on: Wednesday, 11 June 2008, 09:01 CDT
US-based pharmaceutical companies ApoCell and Reata Pharmaceuticals have started a laboratory study, conducted as part of a Phase II clinical trial of Reata RTA 402 for the treatment of diabetic renal disease.
ApoCell develops assays for biomarker expression in circulating tumor and endothelial cells (CTC and CEC). Among other objectives, the RTA 402 diabetic nephropathy study seeks to isolate and enumerate the number of circulating endothelial cells with a specific protein expression profile in patients to monitor the efficacy of treatment response.
Improvement in these biomarkers of endothelial function would suggest that RTA 402 restores proper filtration in the kidney by repairing damaged vasculature and may decrease the severity of cardiovascular complications that are associated with diabetes.
RTA 402 is said to be the lead molecule emerging from Reata's platform of antioxidant inflammation modulators (AIMs). RTA 402 and other AIMs promote the resolution of innate and adaptive immune-mediated inflammation by restoring redox homeostasis in inflamed tissues.
Darren Davis, ApoCell's CEO, said: "This is the first noncancer trial that we are applying our extensive experience in detecting and quantifying expression profiles in circulating rare cells."
Source: Datamonitor
Related Articles
- Circulating Cells Form Bone Outside the Normal Skeleton
- FDA Grants Orphan Drug Status to Reata's RTA 402 for Treatment of Pancreatic Cancer
- Reata Pharmaceuticals Contracts ApoCell to Detect Innovative Biomarkers in a Phase II Clinical Study of RTA 402 for Diabetic Renal Disease
- Results of RTA 402 Phase I Cancer Trial Presented at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
- Industry Leaders Select RTA 402 As Top 10 Most Promising New Cancer Drugs
- RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
- RTA 402 Shown to Prevent Development of Lung Cancer
- New Research Proves RTA 402 Is Potent Inhibitor of NF-kB in Cancer Cells Through Inhibition of IKK
- High Glucose Is Necessary for Complete Maturation of Pdx1-VP16- Expressing Hepatic Cells into Functional Insulin-Producing Cells
- Toshiba Licenses Rambus PCI Express PHY Cell; Agreement Allows for Development of PCI Express ASICs and ASSPs
 |
 |
User Comments (0)
RSS Feeds